TLSA Pitch Deck Teardown: A Clinical-Stage Platform

Tiziana Life Sciences: A Deep Dive into the October 2020 Investor Presentation

Tiziana Life Sciences (NASDAQ: TLSA, AIM: TILS) is a clinical-stage biotechnology company that, at the time of this presentation in October 2020, was positioning itself as a leader in novel drug delivery for monoclonal antibodies. The deck is structured as a traditional life sciences investor presentation, focusing heavily on clinical data, regulatory milestones, and intellectual property rather than the market-size and 'disruption' narratives common in software-centric decks.

Slide 1: Title and Positioning

The cover slide establishes the company's value proposition: an 'Innovative Platform in Oral, Nasal and Inhalation for Monoclonal Antibody Administration.' It highlights three specific clinical focuses: COVID-19 treatment via inhalation, and advanced programs in Crohn’s Disease, progressive Multiple Sclerosis (MS), and Hepatocellular Carcinoma (HCC). The slide also notes the company's dual listing on NASDAQ and AIM, signaling a level of institutional maturity and liquidity.

Slide 4: Scientific Advisory Committee

In biotechnology, the pedigree of the advisors is often as important as the data itself. Slide 4 lists seven prominent MDs and professors. Notable inclusions are Howard Weiner of Harvard Med, a pioneer in mucosal immune system investigation, and Napoleone Ferrara of UC San Diego, the inventor of Avastin (a drug generating $6.67Bn/yr). The committee also includes experts in liver disease and gastroenterology from Italian universities, reflecting the company's international roots and its focus on HCC and Crohn's.

Slide 7: Development Pipeline

This slide provides a visual roadmap of the company's assets. It is divided into three main families:

Foralumab: Three tracks including intranasal for neurodegenerative disease (starting Phase 2 shortly), enteric-coated capsules for Crohn's and NASH (starting Phase 2 shortly), and an I.V. administration track for Crohn's. · TZLS-501 (Anti-IL6R): Focused on COVID-19 via direct lung delivery using a portable inhaler, with an IND submission targeted for Q1 2021. · Milciclib: Three tracks in oncology, most notably an HCC monotherapy that has completed Phase 2a.

The pipeline demonstrates a 'platform' strategy, where a single antibody (like Foralumab) is tested across multiple delivery methods and indications to maximize the probability of a clinical win.

Slide 10: Oral and Nasal Formulation Patents

Slide 10 focuses on the intellectual property and proof-of-concept for Foralumab. It highlights that the nasal delivery technology is in-licensed from Brigham and Women’s Hospital and Harvard Medical School. The slide notes that a Phase 1 study for neurodegenerative diseases was 'well-tolerated up to 250 μg' and that positive top-line data was received in August 2019. A photo of a granted US patent for 'Anti-CD3 Antibody Formulations' is included to provide tangible evidence of IP security.

Slide 13: Clinical Validation in Ulcerative Colitis

To support the oral administration concept, Slide 13 cites a study conducted by Dr. Scott Snapper at Harvard Medical School. The study involved six subjects with moderate-to-severe ulcerative colitis receiving oral OKT3. Key findings included increased anti-inflammatory gene expression and a clinical response in 3 of 6 patients, with one patient in clinical remission. While the sample size is small, the inclusion of a peer-reviewed journal cover (Crohn’s & Colitis 360) adds academic weight to the claim.

Slide 16: COVID-19 Therapeutic Strategy

Reflecting the global context of late 2020, Slide 16 details the company's pivot toward COVID-19. It uses a graph to show the progression from viral infection to 'Hyperinflammation in lungs' and 'Cytokine Storm.' TLSA’s strategy involves using an anti-IL-6R mAb to stop the inflammatory curve before it leads to lung damage or death. The slide explicitly mentions that their patent covers delivery alone or in combination with Remdesivir, a standard of care at the time.

Slide 19: Milciclib Phase 2a Data

This slide presents data from a trial of Milciclib in sorafenib-resistant HCC patients. The trial enrolled 31 patients, with 28 being evaluable. The results were positive for a Phase 2a study: no drug-related deaths, treatment was well-tolerated, and a 'Clinical Benefit Response' of 64% was achieved. A call-out box emphasizes that two patients were continuing compassionate use at 19 months, suggesting long-term durability of the response in some individuals.

Slide 22: Intellectual Property Portfolio

This is a dense, tabular summary of the company's IP. It lists the family, subject, priority date, status, and jurisdiction for their main assets. The priority dates range from 2003 to 2020, and the jurisdictions cover almost every major global market, including the US, EU, China, Japan, and Australia. This slide is designed to reassure investors that the company has a 'moat' that will last through the end of the next decade (2030-2039).

Slide 27: Contact and Headquarters

The final slide provides contact information for the US headquarters in Doylestown, PA, and the UK headquarters in London. It reiterates the three lead assets (Foralumab, TZLS-501, and Milciclib) and the stock tickers. The presence of two physical headquarters and two distinct email contacts for US and UK leadership underscores the company's cross-border operational model.

What Works in the TLSA Deck

Academic Validation: The deck successfully leverages the reputations of Harvard, Yale, and Brigham and Women’s Hospital. In biotech, where the science is complex, these 'stamps of approval' serve as a proxy for quality. Visual Pipeline: Slide 7 is a model for clarity. It allows an investor to immediately understand the stage of every asset and what the next milestone is (e.g., 'Starting Phase 2 shortly'). IP Transparency: The detailed table on Slide 22 is excellent. Many decks simply say 'we have patents,' but TLSA provides the priority dates and jurisdictions, which allows for due diligence.

What is Missing from the TLSA Deck

The Ask: As a public company presentation, there is no specific 'we are raising $X' slide. However, for a private startup, this would be a fatal omission. Financials and Burn: There is no mention of the company's cash position, runway, or historical burn rate. Investors in clinical-stage biotech need to know how much capital is required to reach the next data readout. Competitive Landscape: The deck focuses entirely on TLSA. It does not mention other companies developing anti-IL-6R antibodies (like Roche’s Actemra) or other oral mAb delivery platforms. A competitive matrix would help contextualize their advantage.

Founder Takeaways

Use Peer-Reviewed Evidence: If your startup has been featured in a journal or conducted a study with a major university, feature the journal cover and the lead investigator prominently. It builds immediate trust. Structure Your Pipeline: Even if you only have one product, show the different 'tracks' or indications you are pursuing. It demonstrates that you are building a platform, not just a single product. Be Specific About IP: Don't just say your tech is 'proprietary.' List the status of your patents and the jurisdictions you are targeting. It shows you have a global commercial strategy.